NEONATOLOGY / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Bronchopulmonary dysplasia (BPD) is a chronic lung disease diagnosed in premature infants, which may cause severe respiratory failure due to respiratory syncytial virus (RSV) infection. The aim of this study was to assess the incidence and severity of BPD in infants born before 28 weeks of gestational age (GA) enrolled into the Polish National Program for RSV Prophylaxis (PNPRSVP).

Material and methods:
A retrospective analysis of data on children born in 2013 included in a prophylaxis program during the seasons 2012–2013 and 2013–2014. The following data were evaluated: the need for oxygen therapy for at least 28 days and the need for oxygen therapy at 36 weeks of postmenstrual age (PMA).

Results:
The analysis was carried out in a group of 603 children, who constituted 87.7% of the population entitled to prophylactic administration of palivizumab. BPD was diagnosed in 80.9% of extremely preterm infants; however, in 70.7% of cases the disease was mild. The risk factors for the development of BPD were GA, birth weight and birth weight below the 10th centile for GA. During the program, the median number of doses received was 5 (range: 1–5), and 82.3% of children received all of the expected doses.

Conclusions:
Although the incidence of BPD in extremely preterm infants was high, mainly its mild form was recognized. Monitoring of the incidence of the disease and identifying the risk factors can be carried out effectively based on long-term data collected during the PNPRSVP.
REFERENCES (16)
1.
Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-55.
 
2.
Hilgendorff A, Reiss I, Ehrhardt H, Eickelberg O, Alvira CM. Chronic lung disease in the preterm infant. Lessons learned from animal models. Am J Respir Cell Mol Biol 2014; 50: 233-45.
 
3.
Piedmonte G, Perez MK. Respiratory syncytial virus and bronchiolitis. Pediatr Rev 2014; 35: 519-30.
 
4.
Paes B, Fauroux B, Figueras-Aloy J, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther 2016; 5: 453-71.
 
5.
The Impact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
 
6.
Siffel C, Kistler KD, Lewis JFM, Sarda SP. Global incidence of bronchopulmonary dysplasia among extremely preterm infants: a systematic literature review. J Matern Fetal Neonatal Med 2019; 9: 1-11.
 
7.
Poindexter BB, Feng R, Schmidt B, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc 2015; 12: 1822-30.
 
8.
Ancel PY, Goffinet F, EPIPAGE-2 Writing Group. Survival and morbidity of preterm children born at 22 through 34 weeks’ gestation in France in 2011: results of the EPIPAGE-2 cohort study. JAMA Pediatr 2015; 169: 230-8.
 
9.
Woynarowska M, Rutkowska M, Szamotulska K. Risk factors, frequency and severity of bronchopulmonary dysplasia (BPD) diagnosed according to the new disease definition in preterm neonates. Med Wieku Rozwoj 2008; 12: 933-41.
 
10.
Kwinta P, Grudzień A, Pawlik D, Olechowski W, Lauterbach R, Pietrzyk JJ. Prevalence and risk factors of bronchopulmonary dysplasia among extremely low birth weight newborns of regional birth cohort of south-east Poland. Przegl Lek 2009; 66: 14-20.
 
11.
Rutkowska M, Hożejowski R, Helwich E, Borszewska-Kornacka MK, Gadzinowski J. Severe bronchopulmonary dysplasia – incidence and predictive factors in a prospective, multicenter study in very preterm infants with respiratory distress syndrome. J Matern Fetal Neonatal Med 2019; 32: 1958-64.
 
12.
Reiss I, Landmann E, Heckmann M, Misselwitz B, Gortner L. Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants being small for gestational age. Arch Gynecol Obstet 2003; 269: 40-4.
 
13.
Eriksson L, Haglund B, Odlind V, Altman M, Ewald U, Kieler H. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia. Acta Paediatr 2015; 104: 259-63.
 
14.
Torchin H, Rousseau J, Marchand-Martin L, Truffert P, Jarreau PH, Ancel PY. Palivizumab administration in pre-term infants in France: EPIPAGE-2 cohort study. Arch Pediatr 2018; 25: 89-94.
 
15.
Chan P, Li A, Paes B, et al. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J 2015; 34: e290-7.
 
16.
Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for rsv immunoprophylaxis. J Manag Care Pharm 2010; 16: 46-58.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top